Danaher Q3 Revenues Dip Slightly, Lowers 2012 EPS Guidance | GenomeWeb

NEW YORK (GenomeWeb News) – Danaher today said that revenues in the third quarter were down a fraction of 1 percent year over year as the company missed the consensus Wall Street estimate on the top and bottom line.

For the three months ended Sept. 28, revenues totaled $4.42 billion, compared to $4.45 billion a year ago, and short of the average analyst estimate of $4.51 billion.

Danaher said that core revenues grew 1 percent year over year while acquisitions added 1.5 percent to growth. The impact of currency translations shrank revenues by 3 percent, however.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.